Elevated IL-17A levels in early stages of bladder cancer regardless of smoking status.
The interrelation between nicotine and IL-17A in bladder cancer (BC) patients was investigated. IL-17A in the sera of 121 BC patients who smoked nicotine, 80 nonsmoker BC patients, 29 and 30 age- and sex-matched healthy smokers and nonsmokers were also measured. IL-17A was elevated in smoker and nonsmoker BC patients compared with smoker and nonsmoker controls (p = 0.004 and p = 0.004, respectively). The level of IL-17A in BC patients who smoked both water pipes and cigarettes were the highest (4.35±8.57 pg/ml), followed by BC water pipe users only (1.33±3.122 pg/ml) and cigarette smokers only (0.79±2.26 pg/ml, p = 0.001). IL-17A was elevated in lower stages (I and II) compared with higher stages (III and IV) of the disease (p = 0.013). IL-17A levels are elevated in some BC patients. IL-17A is an important factor in the inflammatory process during tumor progression, either as a defense mechanism or as a tumor-promoting factor.